Surgical Site Infections Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | MinaPharm Pharma, Zurex Pharma, Inc., Merck, Duke Clinical Research Institute

Posted on
by

Surgical Site Infections Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | MinaPharm Pharma, Zurex Pharma, Inc., Merck, Duke Clinical Research Institute
The Key Surgical Site Infections Companies in the market include – MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others.

 

DelveInsight’s “Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Surgical Site Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Surgical Site Infections Market Forecast

 

Some of the key facts of the Market Report:

  • The Surgical Site Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In March 2025, PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company focused on enhancing surgical outcomes, announced the successful completion of patient enrollment in its SHIELD II Phase 3 trial of D-PLEX100. The study aims to prevent surgical site infections in patients undergoing abdominal colorectal surgery. This achievement follows a recommendation from the independent Data Safety Monitoring Board (DSMB), which, after reviewing unblinded efficacy data from the first 430 participants, advised concluding the trial at 800 patients—the minimum planned sample size for reassessment.

  • Findings indicate that surgical site infections occur in 2% to 4% of patients undergoing inpatient surgical procedures.

  • According to the Centers for Disease Control and Prevention, surgical site infections (SSIs) are one of the most common healthcare-associated infections (HAIs), accounting for 22% of all infections. Approximately 2% to 5% of patients undergoing inpatient surgery develop an SSI.

  • A positive shift in treatment options for surgical site infections (SSIs) is anticipated, fueled by the introduction of new therapies and the availability of oxygen therapy, such as Ogenix’s EPIFLO.

  • Key Surgical Site Infections Companies: MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others

  • Key Surgical Site Infections Therapies: Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others

  • The Surgical Site Infections market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Surgical Site Infections pipeline products will significantly revolutionize the Surgical Site Infections market dynamics.

 

Surgical Site Infections Overview

A surgical site infection (SSI) is an infection that emerges following a surgical procedure in the specific area of the body where the surgery was performed. These infections might manifest as superficial ones, affecting solely the skin. However, some SSIs are more severe, potentially involving tissues below the skin’s surface, organs, or implanted materials.

 

Get a Free sample for the Surgical Site Infections Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market

 

Surgical Site Infections Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Surgical Site Infections Epidemiology Segmentation:

The Surgical Site Infections market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Surgical Site Infections

  • Prevalent Cases of Surgical Site Infections by severity

  • Gender-specific Prevalence of Surgical Site Infections

  • Diagnosed Cases of Episodic and Chronic Surgical Site Infections

 

Download the report to understand which factors are driving Surgical Site Infections epidemiology trends @ Surgical Site Infections Epidemiology Forecast

 

Surgical Site Infections Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Surgical Site Infections market or expected to get launched during the study period. The analysis covers Surgical Site Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Surgical Site Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Surgical Site Infections Therapies and Key Companies

  • Ciprodiazole: MinaPharm Pharmaceuticals

  • DFA-02 Antibiotic Gel: Duke Clinical Research Institute

  • ZuraPrep: Zurex Pharma, Inc.

  • Ertapenem: Merck Sharp & Dohme LLC

  • XF-73: Destiny Pharma Plc

  • D-PLEX: PolyPid Ltd.

  • cefuroxime: GlaxoSmithKline

  • Dalbavancin: Durata Therapeutics

  • daptomycin: Cubist Pharmaceutical

  • ZuraGard: Zurex Pharma, Inc.

 

Discover more about therapies set to grab major Surgical Site Infections market share @ Surgical Site Infections Treatment Landscape

 

Scope of the Surgical Site Infections Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Surgical Site Infections Companies: MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others

  • Key Surgical Site Infections Therapies: Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others

  • Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies

  • Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Surgical Site Infections Unmet Needs, KOL’s views, Analyst’s views, Surgical Site Infections Market Access and Reimbursement

 

To know more about Surgical Site Infections companies working in the treatment market, visit @ Surgical Site Infections Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Surgical Site Infections Market Report Introduction

2. Executive Summary for Surgical Site Infections

3. SWOT analysis of Surgical Site Infections

4. Surgical Site Infections Patient Share (%) Overview at a Glance

5. Surgical Site Infections Market Overview at a Glance

6. Surgical Site Infections Disease Background and Overview

7. Surgical Site Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Surgical Site Infections

9. Surgical Site Infections Current Treatment and Medical Practices

10. Surgical Site Infections Unmet Needs

11. Surgical Site Infections Emerging Therapies

12. Surgical Site Infections Market Outlook

13. Country-Wise Surgical Site Infections Market Analysis (2020–2034)

14. Surgical Site Infections Market Access and Reimbursement of Therapies

15. Surgical Site Infections Market Drivers

16. Surgical Site Infections Market Barriers

17. Surgical Site Infections Appendix

18. Surgical Site Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/